eOD-GT8 60mer HIV Vaccine Description
eOD-GT8 60mer HIV Vaccine candidate is designed to stimulate rare immune cells with specific properties. Known as “broadly neutralizing antibodies,” or bnAbs, these specialized blood proteins could attach to HIV spikes, proteins on the virion surface that allow the virus to enter human cells, and disable them via important yet difficult-to-access regions that don’t vary much from strain to strain.
IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.
eOD-GT8 60mer HIV Vaccine Indication
eOD-GT8 60mer HIV Vaccine candidate is indicated to induce broad and potent antibodies to confer protection against HIV, a fast-mutating virus.
eOD-GT8 60mer HIV Vaccine News
February 3, 2021 - First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research. The vaccine showed success in stimulating the production of rare immune cells needed to generate antibodies against the fast-mutating virus; the targeted response was detected in 97% of participants who received the vaccine. The study sets the stage for additional clinical trials that will seek to refine and extend the approach — with the long-term goal of creating a safe and effective HIV vaccine.
January 11, 2021 - Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines. Today's development programs are mRNA vaccine candidates against seasonal flu, HIV, and the Nipah virus.
eOD-GT8 60mer HIV Vaccine Clinical Trials
Clinical Trial NCT03547245: A Phase 1, Randomized, Double-blind, Placebo-controlled Dosage Escalation Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted in HIV-uninfected, Healthy Adult Volunteers
This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative volunteers.
The study is a randomized, double-blind, placebo-controlled dosage-escalation Phase 1 study intended to evaluate the safety and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted in a prime-boost regimen.